Eli Lilly has announced promising results from their latest research on a new GLP-1 pill, marking a significant advancement in diabetes treatment. The pharmaceutical company revealed that this oral medication demonstrated substantial benefits in managing blood sugar levels in individuals with Type 2 diabetes. The GLP-1 pill is designed to improve patient adherence due to its convenient oral form, compared to traditional injectable treatments. Eli Lilly’s data indicates that patients experienced reduced glucose levels and greater ease in managing their condition. This breakthrough has the potential to transform diabetes care for millions worldwide, providing a simpler and effective treatment option. The promising results highlight Eli Lilly’s commitment to innovation in the pharmaceutical industry, pushing forward the boundaries of diabetes management solutions.
ABC NewsNew data shows where most job opportunities are in Kenya for 2026
November 6, 2026
New data reveals the leading regions and sectors in Kenya offering the most job opportunities in 2026. For job seekers in Kenya, understanding where to